Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Cash-to-Debt

: 5.41 (As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Madrigal Pharmaceuticals's cash to debt ratio for the quarter that ended in Dec. 2023 was 5.41.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Madrigal Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Madrigal Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

MDGL' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 350.36 Max: No Debt
Current: 5.41

During the past 13 years, Madrigal Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 0.01. And the median was 350.36.

MDGL's Cash-to-Debt is ranked worse than
52.89% of 1539 companies
in the Biotechnology industry
Industry Median: 6.42 vs MDGL: 5.41

Madrigal Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Madrigal Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Madrigal Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

649.48

361.51

339.21

7.19

5.41

Madrigal Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt																7.19	3.89	2.99	1.99	5.41

Competitive Comparison

For the Biotechnology subindustry, Madrigal Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Madrigal Pharmaceuticals Cash-to-Debt Distribution

For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Madrigal Pharmaceuticals's Cash-to-Debt falls into.

Madrigal Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Madrigal Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	634.131	/	(0.527	+	116.666)
	=	5.41

Madrigal Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	634.131	/	(0.527	+	116.666)
	=	5.41

Madrigal Pharmaceuticals (NAS:MDGL) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Madrigal Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Madrigal Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Madrigal Pharmaceuticals (Madrigal Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Madrigal Pharmaceuticals Inc (NAS:MDGL) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

YDO1:Germany

Address

200 Barr Harbor Drive, Suite 200, Four Tower Bridge, West Conshohocken, PA, USA, 19428

Website

http://www.madrigalpharma.com

Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action.

Executives

Robert E. Waltermire	officer: Senior VP, Chief Pharma Dev.	FOUR TOWER BRIDGE, 200 BARR HARBOR DRIVE, SUITE 200, WEST CONSHOHOCKEN PA 19428
Baker Bros. Advisors Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Brian Joseph Lynch	officer: SVP and General Counsel	480 MORRIS ROAD, BLUE BELL PA 19422
William John Sibold	director, officer: President and CEO	C/O MADRIGAL PHARMACEUTICALS, INC., FOUR, TOWER BRIDGE, 200 BARR HARBOR DR STE 200, WEST CONSHOHOCKEN PA 19428
Felix Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Raymond Cheong	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Richard S Levy	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Remy Sukhija	officer: SVP and Chief Comm'l Officer	48 PHEASANT HILL ROAD, PRINCETON NJ 08540
Alex G. Howarth	officer: Chief Financial Officer	C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bay City Capital Llc	10 percent owner	750 BATTERY STREET STE 400, SAN FRANCISCO CA 94111
Fred B Craves	director, 10 percent owner	750 BATTERY ST, STE 600, SAN FRANCISCO CA 94111